Citations

Showing 10 of 108152 citations.

Anti-PD-1 checkpoint blockade monotherapy in the orthotopic GL261 glioma model: the devil is in the detail
Tritz, Zachariah P. , Johnson, Aaron J. , Ayasoufi, Katayoun , Johnson, Aaron J.

Mayo Clinic

Neuro-Oncology Advances | May 14, 2021 | Volume: 3 | Issue: 1 | Pages: No page available

10.1093/noajnl/vdab066 | PMID 34151268 Get It

Abstract The GL261 cell line, syngeneic on the C57BL/6 background, has, since its establishment half a century ago in 1970, become the most commonly used immunocompetent murine model of glioblastoma. As immunotherapy has entered the mainstream of clinical discourse in the past decade, this model has proved its worth as a formidable opponent against various immunotherapeutic combinations. Although advances in surgical, radiological, and chemotherapeutic interventions have extended mean glioblastoma patient survival by several months, 5-year survival postdiagnosis remains below 5%. Immunotherapeutic interventions, such as the ones explored in the murine GL261 model, may prove beneficial for patients with glioblastoma. However, even common immunotherapeutic interventions in the GL261 model still have unclear efficacy, with wildly discrepant conclusions being made in the literature regarding this topic. Here, we focus on anti-PD-1 checkpoint blockade monotherapy as an example of this pattern. We contend that a fine-grained analysis of how biological variables (age, sex, tumor location, etc.) predict treatment responsiveness in this preclinical model will better enable researchers to identify glioblastoma patients most likely to benefit from checkpoint blockade immunotherapy moving forward.
YouTube Is a Poor‐Quality Source for Patient Information on Rehabilitation and Return to Sports After Hip Arthroscopy
Jildeh, Toufic R. , Abbas, Leena, Washington, Kenneth J., Okoroha, Kelechi R. , Abbas, Muhammad J.

Mayo Clinic

Arthroscopy, Sports Medicine, and Rehabilitation | May 13, 2021 | Volume: 3 | Issue: 4 | Pages: No page available

10.1016/j.asmr.2021.03.011 | PMID 34430885 Get It

Purpose To investigate the information quality on YouTube regarding rehabilitation and return to sport (RTS) after hip arthroscopy. Methods By use of private browsing and predefined search terms, 217 unique videos regarding RTS and rehabilitation after hip arthroscopy were included and systematically reviewed. A total of 164 videos were included in the final analysis. Videos were scored using 4 scoring systems: (1) Journal of the American Medical Association benchmark criteria, (2) the Global Quality Score, (3) a score for RTS after hip arthroscopy, and (4) a score for rehabilitation after hip arthroscopy. Results A large majority of the included videos provided substandard information quality, dependability, and precision. RTS videos that were uploaded by physicians had a significantly higher Journal of the American Medical Association score, Global Quality Score, and RTS score compared with commercial and personal testimony videos ( P = .0003, P = .0021, and P = .0005, respectively). Physician videos pertaining to RTS were also significantly longer than videos in other categories ( P = .0397). Conclusions The quality and reliability of video content on YouTube pertaining to rehabilitation and RTS after hip arthroscopy are generally poor. The educational content of YouTube videos produced by physicians is of significantly higher quality as compared with non‐physicians, patient testimonials, and commercials. Clinical Relevance The quality of the information patients receive on rehabilitation and RTS after hip arthroscopy is important for successful outcomes.
In Reply: Spinal Neurovascular Malformations in Klippel-Trenaunay Syndrome: A Single Center Study
Larson, Anthony S. , Tollefson, Megha M. , Brinjikji, Waleed , Larson, Anthony

Mayo Clinic

Neurosurgery | May 13, 2021 | Volume: 89 | Issue: 3 | Pages: E184-E184

10.1093/neuros/nyab208 | PMID 34161577 Get It

Radiation Exposure and the Neuroanesthesiologist
Pasternak, Jeffrey J.

Mayo Clinic

Journal of Neuroanaesthesiology and Critical Care | May 13, 2021 | Volume: 08 | Issue: 01 | Pages: 001-002

10.1055/s-0041-1725229 Get It

EGFR Inhibitors Plus Bevacizumab are Superior Than EGFR Inhibitors Alone as First-Line Setting in Advanced NSCLC With EGFR Mutations and BIM Deletion Polymorphisms (BIM-CLICaP)
Cardona, Andrés F. , Ordóñez‐Reyes, Camila , Ruíz-Patiño, Alejandro , García-Robledo, Juan Esteban , Barron, L. Zatarain, Recondo, Gonzalo , Rojas, Leonardo , Corrales, Luis , Martín, Claudio , Barrón, Feliciano , Sotelo, Carolina , Rodríguez, July, Ricaurte, Luisa , Ávila, Jenny , Mayorga, D., Archila, Pilar , Otero, Jorge, Bermúdez, Maritza , Gámez, Tatiana , Carranza, Hernán, Vargas, Carlos , Barron, Lucia Zatarain , Rolfo, Christian , Ávila, Jenny , Bermudez, Maritza , Gamez, Tatiana , Rosell, Rafael , Arrieta, Oscar , Cardona, Andrés F , Ordóñez-Reyes, Camila , Garcia-Robledo, Juan Esteban , Sotelo-Rodríguez, Carolina , Rojas, Leonardo , Zatarain-Barrón, Zyanya Lucía , Más, Luís , Rosell, Rafael , Arrieta, Óscar

Mayo Clinic

JCO Precision Oncology | May 13, 2021 | Volume: No volume available | Issue: 5 | Pages: 839-848

10.1200/po.20.00404 | PMID 34994616 Get It

PURPOSE BIM activation is essential for epidermal growth factor receptor ( EGFR)-tyrosine kinase inhibitor (TKI)–triggered apoptosis in EGFR-mutant non–small-cell lung cancer (NSCLC). A deletion in the intron two of the BIM gene results in generation of alternatively spliced isoforms that impairs their apoptotic response to TKIs, conferring the NSCLC cells intrinsic resistance to these medications. Patients with both alterations have poor clinical evolution. The current study aimed to investigate the clinical efficacy and tolerability of EGFR-TKIs plus bevacizumab (Bev) versus EGFR-TKIs alone as first-line treatment in advanced NSCLC patients with EGFR mutations and BIM deletions ( BIMdel). MATERIALS AND METHODS A retrospective analysis was conducted. BIMdel was detected using polymerase chain reaction analysis and direct sequencing of DNA. BIM protein expression was investigated by immunohistochemistry, and BIM mRNA levels by reverse transcriptase-polymerase chain reaction. Clinical characteristics, overall survival, progression-free survival (PFS), overall response rate (ORR), and treatment-related adverse events were compared between both groups. RESULTS Thirty-three patients were included; 15 received EGFR-TKIs, and 18 received EGFR-TKIs plus Bev. The median age was 63 years, with a majority of recruited female patients. All included individuals had an Eastern Cooperative Oncology Group performance score of 2 or less. The addition of Bev resulted in a significantly higher ORR (94.4% v 40%, P > .001). Median PFS was longer with the use of the combination therapy (11.12 v 7.87 months; P = .001). Median overall survival tended to be longer in the EGFR-TKIs plus Bev (30.9 v 25.4 months; P = .06) but failed to reach statistical significance. Response in terms of both partial and complete as well as overall favorably affected PFS. CONCLUSION EGFR-TKIs plus Bev conferred a significantly higher ORR and PFS in advanced NSCLC patients with EGFR mutation and BIMdel. Further prospective studies are needed to validate these findings.
Knowledge-Infused Global-Local Data Fusion for Spatial Predictive Modeling in Precision Medicine
Wang, Lujia , Hawkins‐Daarud, Andrea , Swanson, Kristin R. , Hu, Leland , Li, Jing , Swanson, Kristin R

Mayo Clinic

IEEE Transactions on Automation Science and Engineering | May 13, 2021 | Volume: 19 | Issue: 3 | Pages: 2203-2215

10.1109/tase.2021.3076117 | PMID 37700873 Get It

Brexucabtagene autoleucel therapy induces complete remission in a primary refractory blastoid mantle cell lymphoma with neurolymphomatosis
Khurana, Arushi , Dalland, Joanna , Inwards, David J. , Dalland, Joanna C, Inwards, David J , Paludo, Jonas , Young, Jason R. , Paludo, Jonas

Mayo Clinic

American Journal of Hematology | May 13, 2021 | Volume: 96 | Issue: 8 | Pages: No page available

10.1002/ajh.26233 | PMID 33984157 Get It

Real world outcomes using 20 mm balloon expandable SAPIEN 3/ultra valves compared to larger valves (23, 26, and 29 mm)–a propensity matched analysis
Eng, Marvin H. , Abbas, Amr E. , Wang, Dee Dee , Eleid, Mackram F. , Wang, Dee Dee , Eleid, Mackram F , Hahn, Rebecca T , Lee, James , O’Neill, William W.

Mayo Clinic

Catheterization and Cardiovascular Interventions | May 13, 2021 | Volume: 98 | Issue: 6 | Pages: 1185-1192

10.1002/ccd.29756 | PMID 33984182 Get It

AbstractObjective/BackgroundSmall balloon expandable valves have higher echocardiographic transvalvular gradients and rates of prosthesis‐patient mismatch (PPM) compared to larger valves. However, the impact of these echocardiographic findings on clinical outcomes is unknown. We sought to determine the clinical outcomes of 20 mm SAPIEN 3 (S3 BEV) compared to larger S3 BEV in relation to echocardiographic hemodynamics.MethodsUsing the STS/ACC transcatheter valve registry, we performed a propensity‐matched comparison of patients undergoing treatment of native aortic valve stenosis using transfemoral, balloon‐expandable implantation of 20 mm and ≥ 23 mm S3 BEVs. Baseline and procedure characteristics, echocardiographic variables and survival were analyzed. Multivariable logistic regression was used to identify predictors of 1‐year mortality.ResultsAfter propensity matching of the 20 mm and ≥ 23 mm SAPIEN 3 valves, 3,931 pairs with comparable baseline characteristics were identified. Small valves were associated with significantly higher echocardiographic gradients at discharge (15.7 ± 7.1 mmHg vs. 11.7 ± 5.5 mmHg, p < 0.0001) and severe PPM rates (21.5% vs. 9.7%, p < 0.0001). There was no significant difference in 1‐year all‐cause mortality (20 mm: 13.0% vs. ≥23 mm: 12.7%, p = 0.72) or other major adverse event rates and outcomes between the two cohorts. Based on a multivariable analysis, elevated discharge mean gradient (>20 mmHg), severe PPM and the use of 20 mm versus ≥23 mm were not independent predictors of 1‐year mortality.ConclusionSAPIEN 3 20 mm valves were associated with higher echocardiographic gradients, and severe PPM rates compared to larger valves but these factors were not associated with significant differences in 1‐year all‐cause mortality or rehospitalization.
Factors associated with COVID‐19 in people with Parkinson’s disease: a systematic review and meta‐analysis
Chambergo‐Michilot, Diego , Barros‐Sevillano, Shamir , Rivera‐Torrejón, Oscar , Ku, Gabriel De la Cruz , Custodio, Nilton , De la Cruz-Ku, Gabriel A, De la Cruz-Ku, Gabriel

Mayo Clinic

European Journal of Neurology | May 13, 2021 | Volume: 28 | Issue: 10 | Pages: 3467-3477

10.1111/ene.14912 | PMID 33983673 Get It

AbstractBackgroundThere is debate as to whether there is an increased risk of COVID‐19 infection in people with Parkinson's disease (PD), possibly due to associated factors. This study aimed to systematically review the factors associated with COVID‐19 in people with PD.MethodsA search was carried out in PubMed, Scopus, and Web of Science up to November 2020 (updated until 1 April 2021). Observational studies that analyzed factors associated with COVID‐19 in people with PD were selected and revised.ResultsThe authors included six studies (four case‐controlled studies and two cross‐sectional studies) in the qualitative and quantitative syntheses. The authors found that the following factors were associated with COVID‐19 in people with PD: obesity (OR: 1.79, 95% CI: 1.07–2.99, I2: 0%), any pulmonary disease (OR: 1.92, 95% CI: 1.17–3.15, I2: 0%), COVID‐19 contact (OR: 41.77, 95% CI: 4.77 – 365.56, I2: 0%), vitamin D supplementation (OR: 0.50, 95% CI: 0.30–0.83, I2: 0%), hospitalization (OR: 11.78, 95% CI: 6.27–22.12, I2: 0%), and death (OR: 11.23, 95% CI: 3.92–32.18, I2: 0%). The authors did not find any significant association between COVID‐19 and hypertension, diabetes, cardiopathy, cancer, any cognitive problem, dementia, chronic obstructive pulmonary disease, renal or hepatic disease, smoking, and tremor.ConclusionsMeta‐analyses were limited by the number of events and some methodological limitations. Despite this, the authors assessed the available evidence, and the results may be useful for future health policies.
Epidemiology of Heart Failure
Roger, Véronique L.

Mayo Clinic

Circulation Research | May 13, 2021 | Volume: 128 | Issue: 10 | Pages: 1421-1434

10.1161/circresaha.121.318172 | PMID 33983838 Get It

Designated as an emerging epidemic in 1997, heart failure (HF) remains a major clinical and public health problem. This review focuses on the most recent studies identified by searching the Medline database for publications with the subject headings HF, epidemiology, prevalence, incidence, trends between 2010 and present. Publications relevant to epidemiology and population sciences were retained for discussion in this review after reviewing abstracts for relevance to these topics. Studies of the epidemiology of HF over the past decade have improved our understanding of the HF syndrome and of its complexity. Data suggest that the incidence of HF is mostly flat or declining but that the burden of mortality and hospitalization remains mostly unabated despite significant ongoing efforts to treat and manage HF. The evolution of the case mix of HF continues to be characterized by an increasing proportion of cases with preserved ejection fraction, for which established effective treatments are mostly lacking. Major disparities in the occurrence, presentation, and outcome of HF persist particularly among younger Black men and women. These disturbing trends reflect the complexity of the HF syndrome, the insufficient mechanistic understanding of its various manifestations and presentations and the challenges of its management as a chronic disease, often integrated within a context of aging and multimorbidity. Emerging risk factors including omics science offer the promise of discovering new mechanistic pathways that lead to HF. Holistic management approaches must recognize HF as a syndemic and foster the implementation of multidisciplinary approaches to address major contributors to the persisting burden of HF including multimorbidity, aging, and social determinants of health.